{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:26:24Z","timestamp":1786987584774,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":308,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009403","name":"Menofia\u00a0University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009403","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.curtheres.2021.100654","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T01:47:56Z","timestamp":1636681676000},"page":"100654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study"],"prefix":"10.1016","volume":"95","author":[{"given":"Tarek M.","family":"Mostafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal A.","family":"El-azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal A.","family":"Badra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyaa S.","family":"Abdelwahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer A.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.curtheres.2021.100654_bib0001","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41598-017-17936-4","article-title":"Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions","volume":"8","author":"Kouyoumjian","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.curtheres.2021.100654_bib0002","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1097\/MJT.0b013e3181df8df5","article-title":"Hepatic fibrosis and the renin-angiotensin system","volume":"18","author":"Abbas","year":"2011","journal-title":"Am J Ther"},{"issue":"3","key":"10.1016\/j.curtheres.2021.100654_bib0003","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3904\/kjim.2017.317","article-title":"Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension","volume":"33","author":"Shim","year":"2018","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.curtheres.2021.100654_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s42269-018-0020-7","article-title":"Angiotensin II: a key mediator in the development of liver fibrosis and cancer","volume":"42","author":"Saber","year":"2018","journal-title":"Bull Natl Res Cent"},{"key":"10.1016\/j.curtheres.2021.100654_bib0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.21037\/hbsn.2016.02.06","article-title":"Losartan may inhibit the progression of liver fibrosis in chronic HCV patients","volume":"5","author":"Salama","year":"2016","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"1","key":"10.1016\/j.curtheres.2021.100654_bib0006","doi-asserted-by":"crossref","first-page":"520","DOI":"10.15761\/IMM.1000199","article-title":"Angiotensin II type I receptor blocker, Losartan, inhibits fibrosis in liver by suppressing TGF-beta1 production","volume":"3","author":"Ogata","year":"2016","journal-title":"Integr Mol Med"},{"key":"10.1016\/j.curtheres.2021.100654_bib0007","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/15376516.2015.1124956","article-title":"Angiotensin-converting enzyme inhibitor prevents oxidative stress, inflammation, and fibrosis in carbon tetrachloride-treated rat liver","volume":"26","author":"Reza","year":"2016","journal-title":"Toxicol Mech Methods"},{"key":"10.1016\/j.curtheres.2021.100654_bib0008","first-page":"159","article-title":"Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis","volume":"55","author":"Tuncer","year":"2003","journal-title":"Exp Toxicol Pathol"},{"issue":"1","key":"10.1016\/j.curtheres.2021.100654_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/1470320316628717","article-title":"Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis","volume":"17","author":"Zhu","year":"2016","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.curtheres.2021.100654_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175717","article-title":"A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis","volume":"12","author":"McPherson","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.curtheres.2021.100654_bib0011","doi-asserted-by":"crossref","first-page":"24155","DOI":"10.18632\/oncotarget.23816","article-title":"Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"9","author":"Li","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.curtheres.2021.100654_bib0012","first-page":"481","volume":"24","author":"Bergmeyer","year":"1986","journal-title":"J Clin Chem Clin Biochem"},{"key":"10.1016\/j.curtheres.2021.100654_bib0013","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/clinchem\/31.11.1779","article-title":"Candidate reference method for determination of total bilirubin in serum: development and validation","volume":"31","author":"Doumas","year":"1985","journal-title":"Clin Chem"},{"key":"10.1016\/j.curtheres.2021.100654_bib0014","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0009-8981(96)06447-9","article-title":"Albumin standards and the measurement of serum albumin with bromcresol green","volume":"258","author":"Dumas","year":"1971","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.curtheres.2021.100654_bib0015","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1478-3231.2008.01784.x","article-title":"Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis","volume":"28","author":"Fung","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.curtheres.2021.100654_bib0016","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.curtheres.2021.100654_bib0017","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.curtheres.2021.100654_bib0018","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12072-016-9705-x","article-title":"Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review","volume":"10","author":"Kim","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.curtheres.2021.100654_bib0019","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jnci.2016.06.001","article-title":"Prevalence of hepatocellular carcinoma in chronic hepatitis C patients in Mid Delta, Egypt: a single center study","volume":"28","author":"Ziada","year":"2016","journal-title":"J Egypt Natl Canc Inst"},{"key":"10.1016\/j.curtheres.2021.100654_bib0020","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.3748\/wjg.v11.i48.7560","article-title":"Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study","volume":"11","author":"Sookoian","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.curtheres.2021.100654_bib0021","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection","volume":"97","author":"Regev","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.curtheres.2021.100654_bib0022","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ajg.2013.05.002","article-title":"Role of fibroscan and APRI in detection of liver fibrosis: a systematic review and meta-analysis","volume":"14","author":"Abd El Rihim","year":"2013","journal-title":"Arab J Gastroenterol"},{"issue":"1","key":"10.1016\/j.curtheres.2021.100654_bib0024","first-page":"24","article-title":"Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies","volume":"89","author":"Orasan","year":"2016","journal-title":"Clujul Med."},{"issue":"13","key":"10.1016\/j.curtheres.2021.100654_bib0023","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3390\/molecules26133892","article-title":"Diagnostic accuracy of serum hyaluronan for detecting HCV infection and liver fibrosis in asymptomatic blood donors","volume":"26","author":"Rodart","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.curtheres.2021.100654_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199760","article-title":"APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level","volume":"13","author":"Yen","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.curtheres.2021.100654_bib0026","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.intimp.2018.09.021","article-title":"Lisinopril inhibits nuclear transcription factor kappa B and augments sensitivity to silymarin in experimental liver fibrosis","volume":"64","author":"Saber","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"10.1016\/j.curtheres.2021.100654_bib0027","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3389\/fimmu.2020.01086","article-title":"Role of Kupffer cells in driving hepatic inflammation and fibrosis in HIV infection","volume":"16","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.curtheres.2021.100654_bib0029","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.3389\/fimmu.2019.02852","article-title":"Therapeutic targeting of hepatic macrophages for the treatment of liver diseases","volume":"10","author":"van der Heide","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.curtheres.2021.100654_bib0028","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1155\/2012\/628268","article-title":"Losartan reduces trinitrobenzenesulphonic acid-induced colorectal fibrosis in rats","volume":"26","author":"Wengrower","year":"2012","journal-title":"Can J Gastroenterol"},{"issue":"6","key":"10.1016\/j.curtheres.2021.100654_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520926358","article-title":"Tanshinone IIA alters the transforming growth factor-\u03b21\/Smads pathway in angiotensin II-treated rat hepatic stellate cells","volume":"48","author":"Wei","year":"2020","journal-title":"J Int Med Res"},{"key":"10.1016\/j.curtheres.2021.100654_bib0031","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40139-015-0089-8","article-title":"TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis: updated","volume":"3","author":"Dewidar","year":"2015","journal-title":"Curr Pathobiol Rep"},{"issue":"11","key":"10.1016\/j.curtheres.2021.100654_bib0032","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3390\/cells8111419","article-title":"TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis\u2014updated 2019","volume":"8","author":"Dewidar","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.curtheres.2021.100654_bib0033","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/hr.2009.5","article-title":"Inhibition of the renin-angiotensin system and target organ protection","volume":"32","author":"Iwanami","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1016\/j.curtheres.2021.100654_bib0034","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.3748\/wjg.15.2579","article-title":"Simoes e Silva AC. Renin-angiotensin system in the pathogenesis of liver fibrosis","volume":"15","author":"Pereira","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.curtheres.2021.100654_bib0035","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/cbin.10790","article-title":"Molecular interplays in hepatic stellate cells: apoptosis, senescence, and phenotype reversion as cellular connections that modulate liver fibrosis","volume":"41","author":"de Oliveira da Silva","year":"2017","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.curtheres.2021.100654_bib0036","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1478-3231.2009.01973.x","article-title":"The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C","volume":"29","author":"Corey","year":"2009","journal-title":"Liver Int"},{"issue":"15","key":"10.1016\/j.curtheres.2021.100654_bib0037","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.3390\/ijms21155589","article-title":"Effective combination therapy of angiotensin-II receptor blocker and rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis","volume":"21","author":"Fujinaga","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.curtheres.2021.100654_bib0038","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s10620-010-1507-8","article-title":"The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort","volume":"56","author":"Abu Dayyeh","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.curtheres.2021.100654_bib0039","first-page":"978","article-title":"Effects of angiotensin converting enzyme inhibitors on liver fibrosis in HIV and hepatitis C coinfection","author":"Reese","year":"2012","journal-title":"AIDS Res Treat"},{"issue":"1","key":"10.1016\/j.curtheres.2021.100654_bib0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.curtheres.2021.100654_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.019","article-title":"Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease","volume":"164","author":"Michel","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.curtheres.2021.100654_bib0042","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/ki.1996.505","article-title":"Bradykinin stimulates c-fos expression, AP-1-DNA binding activity and proliferation of rat glomerular mesangial cells","volume":"50","author":"El-Dahr","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.curtheres.2021.100654_bib0043","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tox.2019.01.015","article-title":"Bradykinin contributes to immune liver injury via B2R receptor-mediated pathways in trichloroethylene sensitized mice: a role in Kupffer cell activation","volume":"415","author":"Zhang","year":"2019","journal-title":"Toxicology"},{"key":"10.1016\/j.curtheres.2021.100654_bib0044","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cyto.2018.03.024","article-title":"Role of selective blocking of bradykinin b1 receptor in attenuating immune liver injury in trichloroethylene-sensitized mice","volume":"108","author":"Zhang","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.curtheres.2021.100654_bib0045","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00535-008-2239-9","article-title":"Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model","volume":"43","author":"Kim","year":"2008","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.curtheres.2021.100654_bib0046","first-page":"1","article-title":"Role of hepatic transforming growth factor-\u03921 (TGF- \u03921) and serum hyaluronic acid in the pathogenesis of liver fibrosis in chronic HCV patients","volume":"9","author":"Abbass","year":"2011","journal-title":"AAMJ"},{"issue":"2","key":"10.1016\/j.curtheres.2021.100654_bib0047","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5603\/FHC.a2019.0008","article-title":"The immunoreactivity of TGF-b1 in non-alcoholic fatty liver disease","volume":"57","author":"Kempinski","year":"2019","journal-title":"Folia Histochem Cytobiol"},{"issue":"2","key":"10.1016\/j.curtheres.2021.100654_bib0048","first-page":"1275","article-title":"Study on the association between TGF-\u03b21 and liver fibrosis in patients with hepatic cystic echinococcosis","volume":"19","author":"Tian","year":"2020","journal-title":"Exp Ther Med"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X21000321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X21000321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T22:28:27Z","timestamp":1762122507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X21000321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":48,"alternative-id":["S0011393X21000321"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2021.100654","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2021.100654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100654"}}